EVALUATION OF THE CLINICAL EFFICACY OF THE ... · EVALUATION OF THE CLINICAL EFFICACY OF THE...
1
EVALUATION OF THE CLINICAL EFFICACY OF THE NEPHROPROTECTANTS USED AGAINST RENAL DAMAGE INDUCED BY CISPLATIN THROUGH THE META-ANALYSIS TECHNIQUE Alfredo Ginés CASANOVA 1,2,3 , Laura VICENTE-VICENTE 1,2,3 , María Teresa HERNÁNDEZ- SÁNCHEZ 1,2,3 , Paula TORAL 1,2 , Marta PRIETO 1,2,3 , Moisés PESCADOR 1,2 , Ana Isabel MORALES 1,2,3 1 Toxicology Unit, University of Salamanca, Spain. 2 Translational Research on Renal and Cardiovascular Diseases (TRECARD), University of Salamanca, Spain. 3 Institute of Biomedical Research of Salamanca (IBSAL), Spain. Introduction The main limiting factor of cisplatin is nephrotoxicity; therefore, products that can avoid or reduce it are being investigated. The objective of this work was to carry out a systematic review of the clinical studies evaluating protective substances against cisplatin nephrotoxicity, followed by a meta-analysis. Methods Studies published until December 2017 (Medline and Google Scholar) were identified. After applying the inclusion criteria, 21 studies were selected: Results Conclusion This meta-analysis shows that none of the strategies carried out seem to significantly reduce the damage. In fact, some compounds could even worsen kidney function. That makes further research in this field necessary. Hernández-Sánchez MT is a recipient of a predoctoral fellowship from the Junta de Castilla y León (Spain) and the European Social Fund from the European Commission.
Transcript of EVALUATION OF THE CLINICAL EFFICACY OF THE ... · EVALUATION OF THE CLINICAL EFFICACY OF THE...
EVALUATION OF THE CLINICAL EFFICACY OF THENEPHROPROTECTANTS USED AGAINST RENAL DAMAGE INDUCED BYCISPLATIN THROUGH THE META-ANALYSIS TECHNIQUE
Alfredo Ginés CASANOVA1,2,3, Laura VICENTE-VICENTE1,2,3, María Teresa HERNÁNDEZ-SÁNCHEZ1,2,3, Paula TORAL1,2,Marta PRIETO1,2,3, Moisés PESCADOR1,2, Ana Isabel MORALES1,2,3
1Toxicology Unit, University of Salamanca, Spain.2Translational Research on Renal and Cardiovascular Diseases (TRECARD), University of Salamanca, Spain.3Institute of Biomedical Research of Salamanca (IBSAL), Spain.
Introduction
The main limiting factor of cisplatin is nephrotoxicity;therefore, products that can avoid or reduce it are beinginvestigated. The objective of this work was to carry out asystematic review of the clinical studies evaluatingprotective substances against cisplatin nephrotoxicity,followed by a meta-analysis.
Methods
Studies published until December 2017 (Medline andGoogle Scholar) were identified. After applying theinclusion criteria, 21 studies were selected:
Results
Conclusion
This meta-analysis shows that none of the strategiescarried out seem to significantly reduce the damage. Infact, some compounds could even worsen kidney function.That makes further research in this field necessary.
Hernández-Sánchez MT is a recipient of a predoctoralfellowship from the Junta de Castilla y León (Spain) and theEuropean Social Fund from the European Commission.
